Abstract
The in-between broad acceptance of early surgery and improved intensive care management have led to a significant reduction of vasospasm associated morbidity and mortality within the last 25 years. However, the large body of publications concerned with the prevention and treatment of vasospasm still denote its role as one of the major complications in the postoperative management after aneurysmal subarachnoid hemorrhage (SAH). Next to purely mechanical measures such as balloon dilatation of vasospastic vessels and intraarterial papaverine infusion, which as of now lack verification by means of larger controlled clinical trials, established medical treatment concepts focus on pharmacological approaches such as the calcium antagonist nimodipine and hypervolemic hemodilution and hypertension (“Triple-H” therapy).KeywordsSAHvasospasmtriple-H therapyquality of life
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
